BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 25977146)

  • 1. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial.
    Paul M; Bishara J; Yahav D; Goldberg E; Neuberger A; Ghanem-Zoubi N; Dickstein Y; Nseir W; Dan M; Leibovici L
    BMJ; 2015 May; 350():h2219. PubMed ID: 25977146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial.
    Tong SY; Nelson J; Paterson DL; Fowler VG; Howden BP; Cheng AC; Chatfield M; Lipman J; Van Hal S; O'Sullivan M; Robinson JO; Yahav D; Lye D; Davis JS;
    Trials; 2016 Mar; 17():170. PubMed ID: 27029920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimethoprim/sulfamethoxazole versus vancomycin in the treatment of healthcare/ventilator-associated MRSA pneumonia: a case-control study.
    Eliakim-Raz N; Hellerman M; Yahav D; Cohen J; Margalit I; Fisher S; Zusman O; Shaked H; Bishara J
    J Antimicrob Chemother; 2017 Mar; 72(3):882-887. PubMed ID: 27999052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: a retrospective cohort study.
    Goldberg E; Paul M; Talker O; Samra Z; Raskin M; Hazzan R; Leibovici L; Bishara J
    J Antimicrob Chemother; 2010 Aug; 65(8):1779-83. PubMed ID: 20507860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trimethoprim-sulfamethoxazole monotherapy should not be used for treatment of severe methicillin-resistant Staphylococcus aureus infections.
    Harbarth S
    Evid Based Med; 2015 Aug; 20(4):140. PubMed ID: 26156632
    [No Abstract]   [Full Text] [Related]  

  • 6. External validity of a randomised controlled trial on the treatment of severe infections caused by MRSA.
    Paul M; Bronstein E; Yahav D; Goldberg E; Bishara J; Leibovici L
    BMJ Open; 2015 Sep; 5(9):e008838. PubMed ID: 26362666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.
    Lo DK; Muhlebach MS; Smyth AR
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD009650. PubMed ID: 30030966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection.
    Harbarth S; von Dach E; Pagani L; Macedo-Vinas M; Huttner B; Olearo F; Emonet S; Uçkay I
    J Antimicrob Chemother; 2015 Jan; 70(1):264-72. PubMed ID: 25209610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations: study protocol for a phase IIB randomized controlled trial.
    Kalimuddin S; Phillips R; Gandhi M; de Souza NN; Low JG; Archuleta S; Lye D; Tan TT
    Trials; 2014 Jun; 15():233. PubMed ID: 24943129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia.
    Wi YM; Kim JM; Joo EJ; Ha YE; Kang CI; Ko KS; Chung DR; Song JH; Peck KR
    Int J Antimicrob Agents; 2012 Aug; 40(2):108-13. PubMed ID: 22633565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Administration of Adjuvant β-Lactam Therapy in Combination with Vancomycin among Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: A Retrospective, Multicenter Analysis.
    Casapao AM; Jacobs DM; Bowers DR; Beyda ND; Dilworth TJ;
    Pharmacotherapy; 2017 Nov; 37(11):1347-1356. PubMed ID: 28949410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates.
    Rehm SJ; Boucher H; Levine D; Campion M; Eisenstein BI; Vigliani GA; Corey GR; Abrutyn E
    J Antimicrob Chemother; 2008 Dec; 62(6):1413-21. PubMed ID: 18782781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More accurate measurement of vancomycin minimum inhibitory concentration indicates poor outcomes in meticillin-resistant Staphylococcus aureus bacteraemia.
    Shoji H; Maeda M; Shirakura T; Takuma T; Ugajin K; Fukuchi K; Ishino K; Niki Y
    Int J Antimicrob Agents; 2015 Nov; 46(5):532-7. PubMed ID: 26364848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
    Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
    Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting high vancomycin minimum inhibitory concentration isolate infection among patients with community-onset methicillin-resistant Staphylococcus aureus bacteraemia.
    Chen SY; Hsueh PR; Chiang WC; Huang EP; Lin CF; Chang CH; Chen SC; Chen WJ; Chang SC; Lai MS; Chie WC
    J Infect; 2014 Sep; 69(3):259-65. PubMed ID: 24797078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
    Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS
    Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
    Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations - results of a prematurely terminated study.
    Kalimuddin S; Chan YFZ; Phillips R; Ong SP; Archuleta S; Lye DC; Tan TT; Low JGH
    Trials; 2018 Jun; 19(1):305. PubMed ID: 29859132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy.
    Tenover FC; Sinner SW; Segal RE; Huang V; Alexandre SS; McGowan JE; Weinstein MP
    Int J Antimicrob Agents; 2009 Jun; 33(6):564-8. PubMed ID: 19233622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vancomycin and daptomycin minimum inhibitory concentrations as a predictor of outcome of methicillin-resistant Staphylococcus aureus bacteraemia.
    Ruiz J; Ramirez P; Concha P; Salavert-Lletí M; Villarreal E; Gordon M; Frasquet J; Castellanos-Ortega Á
    J Glob Antimicrob Resist; 2018 Sep; 14():141-144. PubMed ID: 29601996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.